Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats

Background: The Department of Health and Human Services reports that prescription pain reliever (e.g., oxycodone) misuse was initiated by 4,400 Americans each day in 2019. Amid the opioid crisis, effective strategies to prevent and treat prescription opioid use disorder (OUD) are pressing. In precli...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jessica M. Illenberger, Francisco J. Flores-Ramirez, Alessandra Matzeu, Barbara J. Mason, Rémi Martin-Fardon
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-04-01
Serie:	Frontiers in Pharmacology
Soggetti:	prescription opioid use disorder reinstatement dual orexin receptor antagonists oxycodone suvorexant
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1127735/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!